Oncology medicines often reach the market on early data, but payers value overall survival and quality of life. The gap between regulatory and reimbursement evidence is where many oncology access plans stall.
Different questions, different thresholds
A regulator asks whether benefit outweighs risk. A payer asks how much better the medicine is than what is already used, and whether that benefit is certain. Surrogate endpoints such as progression-free survival, response rates and single-arm study results may support approval, yet HTA bodies commonly treat them cautiously until their relationship to patient-relevant outcomes is shown. The joint clinical assessment framework includes guidance on outcomes, adopted on 10 June 2024, which reflects this focus.
The role of the ESMO-MCBS
The ESMO Magnitude of Clinical Benefit Scale is a structured framework that grades the relative size of benefit shown in oncology studies. It uses separate approaches for curative and non-curative settings and is intended to give clinicians, regulators and payers a common reference. It is not a substitute for a formal HTA, but a medicine’s grade can feature in the discussion, so it is worth knowing how your pivotal data would score before a payer calculates it for you.
Evidence planning for oncology
Practical steps can reduce the gap.
- Plan collection of overall survival, quality of life and patient-reported outcomes in the pivotal programme, even where they are secondary.
- Where a single-arm study is unavoidable, prepare an external or indirect comparison early, with pre-specified methods.
- Consider how crossover or subsequent therapy might affect survival results, and prepare to explain it.
- Treat comparator choice as a European question, since practice differs between Member States.
Managing uncertainty with payers
Where uncertainty cannot be removed at launch, a data collection plan may allow access to start while evidence matures. That plan is credible only if endpoints, timelines and consequences are defined in advance. Early dialogue, including joint scientific consultation, is the best moment to test whether your plan will satisfy both regulators and assessors.
Coordinating regulatory and access strategy
Conditional approval and accelerated assessment can bring a medicine to patients sooner, but they may also leave evidence gaps that payers will notice. The regulatory plan should therefore be read alongside the market access plan: what confirmatory data are promised, when will they report, and how will they change the assessment of benefit?
Cross-country differences matter as well. Standard of care for the same tumour type may vary between Member States, which affects which comparator an assessor considers relevant. A single pivotal study cannot always serve every comparator, so it is better to know in advance where an indirect comparison will be necessary and to design it properly rather than to improvise during review.
How PQRA helps
PQRA can help oncology developers review evidence against payer expectations, align regulatory and HTA strategy, and plan the access pathway for Greece and other European markets.
If your oncology programme is approaching a pivotal readout or filing, Contact PQRA.


No responses yet